首页|某院2022年丙戊酸钠血药浓度监测结果分析

某院2022年丙戊酸钠血药浓度监测结果分析

扫码查看
目的 分析某院丙戊酸钠(VPA)血药浓度监测结果及其影响因素,为临床合理用药提供参考。方法 回顾性收集 2022 年 1月~12 月在常熟市第二人民医院行VPA血药浓度监测的 241 例患者资料,采用卡方检验或Fisher精确检验分析年龄、药物剂型及联合用药对VPA血药浓度的影响。结果 241 例患者共行 438 例次VPA治疗药物监测,血药浓度达标率为 58。7%。监测多次的患者中,调整剂量后的监测结果达标率较调整前均有提高。单因素分析显示,剂型和联合用药是影响VPA血药浓度的相关因素(P<0。05)。结论 临床使用丙戊酸钠时应注重血药浓度监测,并及时根据监测结果及临床症状调整给药剂量,以提高抗癫痫治疗效果,降低不良反应发生率。
Analysis of blood concentration monitoring results of sodium valproate in our hospital in 2022
Objective To analyze the monitoring results and factors of blood concentration of sodium valproate(VPA)in our hospital,and to provide reference for clinical rational drug use.Methods The clinical data on 241 patients who were monitored for blood concentration of VPA at Changshu NO.2 People's Hospital from January 2022 to December 2022 was collected and analyzed retrospectively.Chi square test or Fisher's exact test was used to analyze the effects of age,drug dosage form,and combination therapy on VPA blood drug concentration.Results A total of 438 cases of VPA were monitored in 241 patients and 58.7%of which reached the standard.Among the patients with multiple monitoring,the rate of reaching the standard has improved after adjusting the dosage.Univariate analysis showed that the VPA blood drug concentration was related to the dosage form and combination therapy(P<0.05).Conclusion In clinical use of VPA,attention should be paid to therapeutic drug monitoring.The dose should be adjusted timely according to the monitoring results and clinical symptoms to improve clinical efficacy and reduce the adverse reactions.

Sodium valproateBlood concentration monitoringInfluence factorDosage formCombination therapy

江艳、陈川、陶赟、殷秋忆、戴烨

展开 >

常熟市第二人民医院药学部,江苏常熟 215500

丙戊酸钠 血药浓度监测 影响因素 剂型 联合用药

2024

中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
年,卷(期):2024.22(3)
  • 10